Results 201 to 210 of about 812,159 (298)

Carpal Tunnel Syndrome as an Early Underrecognized Feature of Rheumatoid Arthritis: A Population-Based Study of Carpal Tunnel Syndrome Occurrence Before and After Rheumatoid Arthritis Incidence. [PDF]

open access: yesArthritis Care Res (Hoboken)
George RJ   +12 more
europepmc   +1 more source

Outcomes of Tapering Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Multicenter Randomized Noninferiority Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Evidence supporting tapering of biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA) remains limited. We evaluated the efficacy and safety of a structured b/tsDMARD‐tapering strategy in patients with RA who had achieved sustained ...
Dong‐Jin Park   +19 more
wiley   +1 more source

Sema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity‐driven fibrosis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro. Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=
Jaime Marty   +21 more
wiley   +1 more source

The development and validation of a new diagnostic sonographic enthesitis score for psoriatic arthritis: Diagnostic Ultrasound Enthesitis Tool (DUET)

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The Diagnostic Ultrasound Enthesitis Tool (DUET) study aimed to develop and validate a new sonographic scoring system for enthesitis to aid PsA diagnosis. Methods We prospectively enrolled patients with early PsA, psoriasis without arthritis (PsO), and non‐inflammatory musculoskeletal symptoms as controls (CTL) from 17 centers. A standardized
Lihi Eder   +27 more
wiley   +1 more source

Anesthesia for Rheumatoid Arthritis(RA) Patient.

open access: yesTHE JOURNAL OF JAPAN SOCIETY FOR CLINICAL ANESTHESIA, 1997
ARAI, Tatsuru   +9 more
openaire   +2 more sources

Differentiation and Pathologic Significance of Tissue‐Resident Memory‐Like CD8+ T Cells in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Tissue‐resident memory T (TRM) cells have been implicated in organ‐specific immune pathology; however, the pathologic relevance of TRM‐like CD8+ T cells in systemic lupus erythematosus (SLE) remains unclear. We investigated their differentiation mechanisms and pathologic significance in SLE, including associations with disease activity and ...
Yuya Fujita   +10 more
wiley   +1 more source

Spatial Proteomics Identifies Distinct Synovial Microenvironments in Hip and Knee Osteoarthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Osteoarthritis (OA) is a heterogeneous joint disease, yet mechanistic insights derive predominantly from knee OA and are often extrapolated to other joints. We investigated joint‐associated differences in the spatial molecular organization of hip and knee OA synovium.
Peng Xie   +9 more
wiley   +1 more source

Undetectable mannose binding lectin is associated with HRCT proven bronchiectasis in rheumatoid arthritis (RA). [PDF]

open access: yesPLoS One, 2019
Makin K   +6 more
europepmc   +1 more source

Shared and Distinguishing Features of Late‐Onset Rheumatic Diseases Fulfilling Polymyalgia Rheumatica Classification Criteria

open access: yes
Arthritis &Rheumatology, EarlyView.
Kerem Abacar   +5 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy